ClinicalTrials.gg
CompletedNCT00108849Updated Feb 8, 2017

Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

A Phase 3 interventional study of estradiol, 10 mcg in Menopause and Postmenopausal Vaginal Atrophy, sponsored by Novo Nordisk A/S. Completed at 57 sites in 2 countries. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2017-02-08.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Study summary

This trial is conducted in North America. The purpose of this study is to determine if Vagifem Low Dose is an effective and safe treatment for patients suffering from postmenopausal atrophic vaginitis.

02

Conditions studied

  • Menopause
  • Postmenopausal Vaginal Atrophy
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • women whose last menstruation was at least two years previously
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical symptoms

    Time frame: after 12 months

Secondary outcomes

  1. Objective parameters (vaginal Maturation Index/Value and vaginal pH)

  2. Hyperplasia rate

07

Study locations

57 sites
  • Novo Nordisk Investigational Site
    Mobile, Alabama 36608, United States
  • Novo Nordisk Investigational Site
    Montgomery, Alabama 36106, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85050, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85712, United States
  • Novo Nordisk Investigational Site
    Carmichael, California 95608, United States
  • Novo Nordisk Investigational Site
    Palo Alto, California 94304, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92108, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92123, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80218, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80220, United States
  • Novo Nordisk Investigational Site
    Lakewood, Colorado 80228, United States
  • Novo Nordisk Investigational Site
    New London, Connecticut 06320, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33759, United States
  • Novo Nordisk Investigational Site
    Daytona Beach, Florida 32114, United States
  • Novo Nordisk Investigational Site
    Palm Springs, Florida 33461, United States
  • Novo Nordisk Investigational Site
    Plantation, Florida 33324, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33607, United States
  • Novo Nordisk Investigational Site
    West Palm Beach, Florida 33409, United States
  • Novo Nordisk Investigational Site
    Alpharetta, Georgia 30005, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30075, United States
  • Novo Nordisk Investigational Site
    Boise, Idaho 83702, United States
  • Novo Nordisk Investigational Site
    Peoria, Illinois 61615, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40536-0293, United States
  • Novo Nordisk Investigational Site
    Laurel, Maryland 20707, United States
  • Novo Nordisk Investigational Site
    Lincoln, Nebraska 68510, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Moorestown, New Jersey 08057, United States
  • Novo Nordisk Investigational Site
    New York City, New York 10016, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28209, United States
  • Novo Nordisk Investigational Site
    Mount Airy, North Carolina 27030, United States
  • Novo Nordisk Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Novo Nordisk Investigational Site
    Cleveland, Ohio 44122, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43210, United States
  • Novo Nordisk Investigational Site
    Eugene, Oregon 97401, United States
  • Novo Nordisk Investigational Site
    Medford, Oregon 97504, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19114, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15206, United States
  • Novo Nordisk Investigational Site
    West Reading, Pennsylvania 19611, United States
  • Novo Nordisk Investigational Site
    Charleston, South Carolina 29401, United States
  • Novo Nordisk Investigational Site
    Columbia, South Carolina 29201, United States
  • Novo Nordisk Investigational Site
    Greenville, South Carolina 29607, United States
  • Novo Nordisk Investigational Site
    Jackson, Tennessee 38305, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38120, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030, United States
  • Novo Nordisk Investigational Site
    Sandy, Utah 84070, United States
  • Novo Nordisk Investigational Site
    Norfolk, Virginia 23507, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99204, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99207, United States
  • Novo Nordisk Investigational Site
    Tacoma, Washington 98405, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Novo Nordisk Investigational Site
    Kingston, K7L 4P8, Canada
  • Novo Nordisk Investigational Site
    Montreal, H1T 1P6, Canada
  • Novo Nordisk Investigational Site
    Quebec City, G1S 2L6, Canada
  • Novo Nordisk Investigational Site
    Toronto, M5C 1R6, Canada
  • Novo Nordisk Investigational Site
    Toronto, M5G 1Z5, Canada
  • Novo Nordisk Investigational Site
    Winnipeg, R3A 1M3, Canada
08

References and documents

Publications

  • Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas. 1991 Dec;14(1):23-31. doi: 10.1016/0378-5122(91)90144-f. PubMed 1791769 ↗
  • Derzko CM, Rohrich S, Panay N. Does age at the start of treatment for vaginal atrophy predict response to vaginal estrogen therapy? Post hoc analysis of data from a randomized clinical trial involving 205 women treated with 10 mug estradiol vaginal tablets. Menopause. 2020 Oct 5;28(2):113-118. doi: 10.1097/GME.0000000000001666. PubMed 33038141 ↗
  • Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010 Oct;116(4):876-883. doi: 10.1097/AOG.0b013e3181f386bb. PubMed 20859151 ↗
  • Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol. 2008 Nov;112(5):1053-60. doi: 10.1097/AOG.0b013e31818aa7c3. Erratum In: Obstet Gynecol. 2008 Dec;112(6):1392. PubMed 18978105 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2005
First posted
Apr 20, 2005
Start
Mar 2005
Primary completionActual
May 2007
CompletionActual
May 2007
Last update
Feb 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00108849
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 20, 2005
Start date
Mar 2005
Primary completion
May 2007
Completion
May 2007
Last update
Feb 8, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion